Ocugen, Inc. declares commencement of Phase 1/2 trial after first administration on patient for OCU410ST - a modifier gene therapy for Stargardt Disease, assessing its safety and effectiveness.

This article summarized the latest R&D progress of Sevelamer Hydrochloride, the Mechanism of Action for Sevelamer Hydrochloride, and the drug target R&D trends for Sevelamer Hydrochloride.

Sana Biotech Reveals FDA Approval of New Drug Application for SC291, a Hypoimmune-modified, Targeting CD19, Allogeneic CAR T Treatment, Targeted for Lupus Nephritis, Extrarenal Lupus, and ANCA-linked Vasculitis Patients.

The disclosure of the clinical trial of Trastuzumab deruxtecan (T-DXd) for the pretreatment of patients (pts) with her2-expressing solid tumors at ESMO 2023 provides the factual basis for subsequent, more in-depth studies.

US FDA has given the green light to Takeda's ADZYNMA (recombinant-krhn, ADAMTS13) for the management of Congenital Thrombotic Thrombocytopenic Purpura (cTTP).

This article summarized the latest R&D progress of Spiramycin, the Mechanism of Action for Spiramycin, and the drug target R&D trends for Spiramycin.

Boston Pharma shares promising Phase 2a results for potential once-a-month BOS-580 treatment in NASH and its impact on diabetic groups, showcased at the 2023 AASLD Liver Meeting.

On 23 Oct 2023, the clinical results of Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1% was reported at the ESMO Congress.

Sirius Therapeutics reports its application to initiate the primary clinical testing of Factor XI siRNA, an advanced, long-lasting anticoagulant for blood clot issues.

This article summarized the latest R&D progress of Sulfamethazine, the Mechanism of Action for Sulfamethazine, and the drug target R&D trends for Sulfamethazine.

Trishula Therapeutics kickstarts Phase 2 study of TTX-030, a compound directed against CD39, in initial treatment of patients with advanced pancreatic cancer.

The clinical trial for Capmatinib Hydrochloride took center stage at the 2023 ESMO Congress, demonstrating its potential to treat aNSCLC.